Profile data is unavailable for this security.
About the company
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
- Revenue in USD (TTM)0.00
- Net income in USD-101.76m
- Incorporated2014
- Employees102.00
- LocationOric Pharmaceuticals Inc240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 388-5600
- Fax+1 (302) 655-5049
- Websitehttp://oricpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Olema Pharmaceuticals Inc | 0.00 | -96.66m | 606.67m | 74.00 | -- | 2.35 | -- | -- | -2.16 | -2.16 | 0.00 | 4.62 | 0.00 | -- | -- | 0.00 | -39.24 | -30.06 | -42.54 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| GH Research PLC | 0.00 | -35.59m | 623.82m | 49.00 | -- | 2.85 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Novavax Inc | 983.71m | -545.06m | 627.60m | 1.54k | -- | -- | -- | 0.638 | -5.53 | -5.53 | 9.42 | -5.14 | 0.485 | 8.76 | 5.18 | 637,527.60 | -26.88 | -46.06 | -- | -269.57 | 65.10 | -- | -55.41 | -75.94 | 0.6741 | -38.31 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 637.34m | 224.00 | -- | 1.06 | -- | 9,372.68 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| enGene Holdings Inc | 0.00 | -106.80m | 640.35m | 33.00 | -- | 5.40 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
| Zymeworks Inc | 50.46m | -125.97m | 640.59m | 275.00 | -- | 1.47 | -- | 12.69 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| SNDL Inc | 662.54m | -122.54m | 640.81m | 2.52k | -- | 0.7317 | -- | 0.9672 | -0.4704 | -0.4831 | 2.56 | 3.36 | 0.5995 | 5.29 | 36.58 | 263,331.00 | -11.34 | -24.44 | -12.28 | -27.94 | 24.17 | 22.49 | -18.92 | -62.17 | 2.69 | -9.29 | 0.1196 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Prime Medicine Inc | 0.00 | -198.13m | 643.35m | 234.00 | -- | 3.92 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -101.76m | 647.25m | 102.00 | -- | 1.97 | -- | -- | -1.81 | -1.81 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -35.25 | -33.92 | -37.18 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Castle Biosciences Inc | 250.73m | -30.80m | 649.87m | 610.00 | -- | 1.61 | -- | 2.59 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Hillevax Inc | 0.00 | -123.57m | 670.24m | 90.00 | -- | 2.42 | -- | -- | -3.04 | -3.04 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.35 | -- | -39.90 | -- | -- | -- | -- | -- | -- | -- | 0.0868 | -- | -- | -- | 22.68 | -- | -- | -- |
| SS Innovations International Inc | 5.88m | -20.94m | 682.90m | 239.00 | -- | 47.76 | -- | 116.14 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Savara Inc | 0.00 | -54.70m | 689.50m | 37.00 | -- | 4.91 | -- | -- | -0.3424 | -0.3424 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -34.47 | -36.86 | -36.36 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.158 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Data as of May 09 2024. Currency figures normalised to Oric Pharmaceuticals Inc's reporting currency: US Dollar USD
42.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 6.42m | 9.53% |
| Viking Global Investors LPas of 20 Jan 2024 | 4.00m | 5.94% |
| Alkeon Capital Management LLCas of 31 Dec 2023 | 3.60m | 5.35% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 3.42m | 5.07% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.78m | 4.12% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.21m | 3.29% |
| Silverbay Capital Management LLCas of 31 Dec 2023 | 1.76m | 2.62% |
| ArrowMark Colorado Holdings LLCas of 31 Dec 2023 | 1.73m | 2.57% |
| Prosight Management LPas of 31 Dec 2023 | 1.58m | 2.34% |
| SilverArc Capital Management LLCas of 31 Dec 2023 | 1.17m | 1.74% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
